Press release
Long-Term Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) should contact the Shareholders Foundation in connection with the Investigation over potential Wrongdoing by certain directors
An investigation on behalf of current long term investors in Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) shares.
Investors who are current long term investors in Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: MRNS stocks follows a lawsuit filed against Marinus Pharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: MRNS stocks, concerns whether certain Marinus Pharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges that, the defendants made materially false and/or misleading statements and/or failed to disclose that defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial, that defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial, and that as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times
Those who purchased shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Long-Term Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) should contact the Shareholders Foundation in connection with the Investigation over potential Wrongdoing by certain directors here
News-ID: 3886717 • Views: …
More Releases from Shareholders Foundation, Inc.
Ready Capital Corporation (NYSE: RC) Long Term Investor Investigation of potenti …
An investigation was announced for potential breaches of fiduciary duties by certain directors and officers of Ready Capital Corporation.
Investors who are current long term investors in Ready Capital Corporation (NYSE: RC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: RC stocks follows a lawsuit filed against Ready…
Investigation announced for Long-Term Investors in shares of Digimarc Corporatio …
An investigation was announced for current long-term investors in shares of Digimarc Corporation (NASDAQ: DMRC) concerning potential breaches of fiduciary duties by certain directors of Digimarc Corporation.
Investors who are current long term investors in Digimarc Corporation (NASDAQ: DMRC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: DMRC…
Ultra Clean Holdings, Inc. (NASDAQ: UCTT) Investor Alert: Deadline in Lawsuit on …
A deadline is coming up on May 23, 2025 in the lawsuit filed for certain investors of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) over alleged securities laws violations by Ultra Clean Holdings, Inc.
Investors who purchased shares of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) have certain options and there are strict and short deadlines running. Deadline: May 23, 2025. Ultra Clean Holdings, Inc. (NASDAQ: UCTT) stockholders should contact the Shareholders…
Lawsuit filed for Investors who lost money with shares of West Pharmaceutical Se …
An investor, who purchased shares of West Pharmaceutical Services, Inc. (NYSE: WST), filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania over alleged violations of Federal Securities Laws by West Pharmaceutical Services, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of West Pharmaceutical Services, Inc. (NYSE: WST) have certain options and for certain investors are short and strict deadlines running.…
More Releases for Marinus
Status Epilepticus Market to Witness Upsurge in Growth During the Forecast Perio …
As per DelveInsight, Status Epilepticus Therapeutics Market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and the expected launch of emerging therapies.
DelveInsight's "Status Epilepticus Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Status Epilepticus Market…
CDKL5 Deficiency Disorder Market to Register Sustainable Growth During the Forec …
DelveInsight's "CDKL5 Deficiency Disorder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the CDKL5 Deficiency Disorder Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The CDKL5 Deficiency Disorder market report covers emerging drugs, treatment practices, market share of the individual therapies, and current &…
Status Epilepticus Market See Incredible Growth 2022-2028 | SAGE Therapeutics, …
The exclusive research report on 'Status Epilepticus Market' now available with 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, offers a detailed analysis of the factors influencing the global business sphere. This report also provides precise information pertaining to market size, commercialization aspects and revenue estimation of this business. The report further elucidates the status of leading industry players thriving in the competitive spectrum of the Status Epilepticus Market.
The research report incorporates a detailed evaluation…
Status Epilepticus Market Is Booming Worldwide 2021-2028 | SAGE Therapeutics, Ma …
The Status Epilepticus Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The Status Epilepticus Market study includes research on the top markets based on all the data from the elite players, current, past and future. Major companies in the Status Epilepticus were identified through the second survey and…
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Impulsive Hike …
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a developmental encephalopathy caused by pathogenic variants in the gene CDKL5. This unique disorder includes early infantile-onset refractory epilepsy, hypotonia, developmental intellectual and motor disabilities, and cortical visual impairment.
CDKL5 deficiency disorder is a genetic disorder that causes seizures, developmental delay, and severe intellectual disability. Seizures typically begin within a few months after birth and are difficult to control with medications.
The CDKL5…
Fragile X Syndrome Market To See Ongoing Evolution 2027 | Aelis Farma SAS, Alcob …
Fragile X Syndrome Market Research Study Outlook 2020 - The exploration report comprised with market data derived from primary as well as secondary research techniques. The points covered in this study are primarily factors which are considered to be market driving forces. The aim is to get premium insights, quality data figures and information in relation to aspects such as market scope, market size, share, and segments including Types of…
